カテゴリー： 世界

Global Prescription Digital Therapeutics (PDTx) Market – Industry Trends and Forecast to 2027

Data Bridge Market Researchが出版した調査資料（DBM890SP8110）・商品コード：DBM890SP8110
・発行会社（調査会社）：Data Bridge Market Research
・発行日：2020年12月
・ページ数：350
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用、印刷不可）USD4,800 ⇒換算￥729,600見積依頼/購入/質問フォーム
Enterprise User（法人閲覧用、印刷可能）USD7,000 ⇒換算￥1,064,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Global Prescription Digital Therapeutics (PDTx) Market, By Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software for Respiratory Conditions, Software for Mental Health, Software for Opioid Use Disorder, Software for Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2027.

The prescription digital therapeutics (PDTx) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.6% in the forecast period of 2020 to 2027 and is expected to reach USD 2,698.99 million by 2027. Rising prevalence of metabolic diseases such as diabetics and continuous monitoring of diseases everywhere and extensive research & development activity in prescription digital therapeutics (PDTx) are the major drivers which propelled the demand of the prescription digital therapeutics (PDTx) market in the forecast period.

The prescription digital therapeutics (PDTx) comprises features such as increasing need for effective treatment for chronic diseases which will impact in launching of new products by the manufacturers into the market which enhance its demand as well as rising pharmaceutical industries initiatives leads to the prescription digital therapeutics (PDTx) market growth.

Currently, various research & clinical studies are going on which is expected to create a competitive advantage for manufacturers to develop new and innovative technology. Moreover, these clinical programmes are also expected to provide various other opportunities in the prescription digital therapeutics (PDTx) market. However, lack of awareness in rural countries and high cost of therapeutics are expected to restraint the prescription digital therapeutics (PDTx) market growth in the forecast period.

The prescription digital therapeutics (PDTx) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the prescription digital therapeutics (PDTx) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

❖ レポートの目次 ❖

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 MECHANISM OF PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INESIGHT

4.1 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET: LAWS AND REGULATIONS

4.2 PRINCIPLES FOR THE DEVELOPMENT OF PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) GUIDELINES

4.3 HIPAA COMPLIANCE FOR PRESCRIPTION DIGITAL THERAPEUTICS (PDTX)

5 EPIDERMOLOGY

6 PIPELINE ANALYSIS

6.1 LIST OF PIPELINE PRODUCTS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 PRESENCE OF PRODUCT PIPELINE

7.1.2 INCREASING PREVALANCE OF DISEASES

7.1.3 HIGH DEMAND OF PDTX DUE TO THEIR HIGH COST EFFECTIVENESS

7.1.4 INCREASINGLY DOMINANT ROLE OF MOBILE TECHNOLOGY AND ARTIFICIAL INTELLIGENCE (AI) IN OUR EVERYDAY LIVES

7.1.5 PRESENCE OF REIMBURSEMENT

7.2 RESTRAINTS

7.2.1 UNAFFORDABILITY OF DIGITAL THERAPEUTICS

7.2.2 PRIVACY ISSUES IN PRESCRIPTION DIGITAL HEALTHCARE

7.2.3 RESISTANCE FROM TRADITIONAL HEALTHCARE PROVIDERS

7.3 OPPORTUNITIES

7.3.1 INCREASING FUNDING ACTIVITIES

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.3 EXPLORATION OF EMERGING MARKET

7.3.4 INCREASING HEALTHCARE EXPENDITURE

7.4 CHALLENGES

7.4.1 LACK OF SKILLED RESOURCES

7.4.2 EXISTENCE OF TRADITIONAL MEDICATIONS

7.4.3 LONG APPROVAL PROCEDURE

8 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC DECISIONS FOR MANUFACTURERS

8.5 CONCLUSION

9 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY MECHANISM

9.1 OVERVIEW

9.2 INPUT MECHANISMS

9.2.1 PATIENT DATA COLLECTION

9.2.1.1 Cognition

9.2.1.2 Mood

9.2.1.3 Memory

9.2.1.4 Concentration

9.2.1.5 Familial Recognition

9.2.1.6 Others

9.2.2 DEXTERITY OR STEADINESS MEASUREMENT

9.2.2.1 Range of Motion Tests

9.2.2.2 Stretching

9.2.2.3 Others

9.2.3 AUDIO ANALYSIS

9.2.3.1 Shakiness

9.2.3.2 Voice Quality

9.2.3.3 Others

9.2.3.4 Screen

9.2.3.5 Accelerometer

9.2.3.6 Microphone

9.3 OUTPUT MECHANISMS

9.3.1 PATIENT COMMUNICATION

9.3.1.1 Professional Coaching

9.3.1.2 Peer-to-Peer Support

9.3.1.3 Others

9.3.2 ADHERENCE PROMPTS

9.3.2.1 Sleep

9.3.2.2 Diet

9.3.2.3 Inactivity

9.3.2.4 Others

9.3.3 CONTENT DELIVERY

9.3.3.1 Blogs

9.3.3.2 Tips

9.3.3.3 Videos

9.3.3.4 FAQs

9.3.3.5 Others

9.3.3.6 Chat

9.3.3.7 Notification

10 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY CATEGORY

10.1 OVERVIEW

10.2 MEDICATION AUGMENTATION

10.3 MEDICATION REPLACEMENT

11 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY TREATMENT

11.1 OVERVIEW

11.2 OUTPATIENT TREATMENT

11.2.1 COGNITIVE BEHAVIOR THERAPY (CBT)

11.2.2 CONTINGENCY MANAGEMENT

11.2.3 CRAVING OR TRIGGER ASSESSMENT

11.2.4 FLUENCY TRAINING

11.2.5 TRANSMUCOSAL BUPRENORPHINE

11.2.6 OTHERS

11.3 MONOTHERAPY

11.3.1 COGNITIVE RESTRUCTURING

11.3.2 INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBT)

11.3.3 OTHERS

12 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY SOFTWARE

12.1 OVERVIEW

12.2 4.2 SOFTWARE FOR DIABETES

12.3 SOFTWARE FOR MENTAL HEALTH

12.4 SOFTWARE FOR RESPIRATORY CONDITIONS

12.5 SOFTWARE FOR OPIOID USE DISORDER

12.6 OTHERS

13 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY SERVICES

13.1 OVERVIEW

13.2 BEHAVIORAL MICROSERVICES

13.2.1 PHYSICAL ACTIVITY

13.2.2 TELEMEDICINE

13.2.3 CONTROLLED BREATHING

13.2.4 MINDFULNESS TRAINING

13.2.5 RELAXATION TECHNIQUE

13.2.6 DIET OPTIMIZATION

13.2.7 OTHERS

13.3 MEDICAL MICROSERVICES

13.3.1 MEDICATION MANAGEMENT SYSTEM

13.3.2 PATIENT HEALTH QUESTIONNAIRE

13.3.3 HEALTH RECOVERED ENGINE

13.3.4 FAGERSTRÖM TEST

13.3.5 MORISKY MEDICATION ADHERENCE SCALE

13.3.6 FINANCIAL SAVING ENGINE

13.3.7 OTHERS

14 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY APP ACCESSIBILITY

14.1 OVERVIEW

14.2 ANDROID

14.2.1 SMARTPHONE

14.2.2 TABLET

14.3 OS

14.3.1 SMARTPHONE

14.3.2 TABLET

14.4 WINDOWS

14.4.1 SMARTPHONE

14.4.2 TABLET

15 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY APP TYPE

15.1 OVERVIEW

15.2 NATIVE APPS

15.3 WEB APPS

16 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY APPLICATION

16.1 OVERVIEW

16.2 METABOLIC CONDITIONS

16.3 MAJOR DEPRESSIVE DIORDER (MDD)

16.4 RESPIRATORY

16.5 CARDIOVASCULAR

16.6 SUBSTANCE USE DISORDER (SUD)

16.7 OPIOID USE DISORDERS (OUD)

16.8 INSOMNIA

16.9 PAIN MANAGEMENT

16.1 ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)

16.11 MOVEMENT DISORDER

16.12 INFLAMMATION

16.13 ONCOLOGY

16.14 MIGRAINE

16.15 ALZHEIMER’S DISEASE

16.16 EPILEPSY

16.17 MULTIPLE SCLEROSIS

16.18 AUSTISM SPECTRUM DISORDER

16.19 OTHERS

17 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY PATIENTS

17.1 OVERVIEW

17.2 ADULTS

17.3 CHILDREN

18 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET, BY GEOGRAPHY

18.1 OVERVIEW

18.2 NORTH AMERICA

18.2.1 U.S.

18.2.2 CANADA

18.2.3 MEXICO

18.3 EUROPE

18.3.1 GERMANY

18.3.2 FRANCE

18.3.3 ITALY

18.3.4 U.K

18.3.5 SPAIN

18.3.6 NETHERLANDS

18.3.7 RUSSIA

18.3.8 SWITZERLAND

18.3.9 TURKEY

18.3.10 AUSTRIA

18.3.11 NORWAY

18.3.12 HUNGARY

18.3.13 LITHUANIA

18.3.14 IRELAND

18.3.15 POLAND

18.3.16 REST OF EUROPE

18.4 ASIA -PACIFIC

18.4.1 JAPAN

18.4.2 CHINA

18.4.3 AUSTRALIA

18.4.4 SOUTH KOREA

18.4.5 INDIA

18.4.6 SINGAPORE

18.4.7 THAILAND

18.4.8 MALAYSIA

18.4.9 INDONESIA

18.4.10 PHILIPPINES

18.4.11 VIETNAM

18.4.12 REST OF ASIA- PACIFIC

18.5 SOUTH AMERICA

18.5.1 BRAZIL

18.5.2 RGENTINA

18.5.3 PERU

18.5.4 REST OF SOUTH AMERICA

18.6 MIDDLE EAST & AFRICA

18.6.1 SAUDI ARABIA

18.6.2 SOUTH AFRICA

18.6.3 UAE

18.6.4 ISRAEL

18.6.5 KUWAIT

18.6.6 EGYPT

18.6.7 REST OF MIDDLE EAST & AFRICA

19 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET: COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: GLOBAL

19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

19.3 COMPANY SHARE ANALYSIS: EUROPE

19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

20 SWOT ANALYSIS

21 COMPANY PROFILE

21.1 OMADA HEALTH, INC.

21.1.1 COMPANY SNAPSHOT

21.1.2 PRODUCT PORTFOLIO

21.1.3 RECENT DEVELOPMENTS

21.2 RESMED

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 COMPANY SHARE ANALYSIS

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 SAMSUNG

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE ANALYSIS

21.3.3 COMPANY SHARE ANALYSIS

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENT

21.4 GAIA AG

21.4.1 COMPANY SNAPSHOT

21.4.2 COMPANY SHARE ANALYSIS

21.4.3 PRODUCT PORTFOLIO

21.4.4 RECENT DEVELOPMENTS

21.5 PEAR THERAPEUTICS, INC.

21.5.1 COMPANY SNAPSHOT

21.5.2 COMPANY SHARE ANALYSIS

21.5.3 PRODUCT PORTFOLIO

21.5.4 RECENT DEVELOPMENTS

21.6 WELLDOC’S BLUESTAR

21.6.1 COMPANY SNAPSHOT

21.6.2 PRODUCT PORTFOLIO

21.6.3 RECENT DEVELOPMENTS

21.7 SOLERA NETWORK

21.7.1 COMPANY SNAPSHOT

21.7.2 PRODUCT PORTFOLIO

21.7.3 RECENT DEVELOPMENTS

21.8 AKILI INTERACTIVE LABS, INC.

21.8.1 COMPANY SNAPSHOT

21.8.2 PRODUCT PORTFOLIO

21.8.3 RECENT DEVELOPMENTS

21.9 BETTER THERAPEUTICS, LLC

21.9.1 COMPANY SNAPSHOT

21.9.2 PIPELINE PRODUCT PORTFOLIO

21.9.3 RECENT DEVELOPMENTS

21.1 BIGHEALTH

21.10.1 COMPANY SNAPSHOT

21.10.2 SOLUTION PORTFOLIO

21.10.3 RECENT DEVELOPMENT

21.11 BIOFOURMIS

21.11.1 COMPANY SNAPSHOT

21.11.2 PRODUCT PORTFOLIO

21.11.3 RECENT DEVELOPMENTS

21.12 CLICK THERAPEUTICS, INC.

21.12.1 COMPANY SNAPSHOT

21.12.2 PRODUCT PORTFOLIO

21.12.3 RECENT DEVELOPMENTS

21.13 HAPPIFY, INC.

21.13.1 COMPANY SNAPSHOT

21.13.2 PRODUCT PORTFOLIO

21.13.3 RECENT DEVELOPMENTS

21.14 LIMBIX HEALTH, INC.

21.14.1 COMPANY SNAPSHOT

21.14.2 PRODUCT PORTFOLIO

21.14.3 RECENT DEVELOPMENTS

21.15 NATURALCYCLES NORDIC AB

21.15.1 COMPANY SNAPSHOT

21.15.2 PRODUCT PORTFOLIO

21.15.3 RECENT DEVELOPMENTS

21.16 NUVOAIR AB

21.16.1 COMPANY SNAPSHOT

21.16.2 PRODUCT PORTFOLIO

21.16.3 RECENT DEVELOPMENTS

21.17 SENSYNE HEALTH PLC

21.17.1 COMPANY SNAPSHOT

21.17.2 REVENUE ANALYSIS

21.17.3 PRODUCT PORTFOLIO

21.17.4 RECENT DEVELOPMENTS

21.18 VOLUNTIS

21.18.1 COMPANY SNAPSHOT

21.18.2 REVENUE ANALYSIS

21.18.3 PRODUCT PORTFOLIO

21.18.4 RECENT DEVELOPMENTS

21.19 XEALTH

21.19.1 COMPANY SNAPSHOT

21.19.2 PRODUCT PORTFOLIO

21.19.3 RECENT DEVELOPMENTS

22 QUESTIONNAIRE

23 RELATED REPORTS



★調査レポート[Global Prescription Digital Therapeutics (PDTx) Market – Industry Trends and Forecast to 2027] (コード：DBM890SP8110)販売に関する免責事項を必ずご確認ください。
★調査レポート[Global Prescription Digital Therapeutics (PDTx) Market – Industry Trends and Forecast to 2027]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • Automotive Camera Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
  • ALD Equipment Market – Global Forecast to 2027
  • Global Drawn Wire Market Insights, Forecast to 2027
  • Global and Japan FRP Rebar Market Insights, Forecast to 2027
  • Global Bike-Sharing Service Market Size, Status and Forecast 2021-2027
  • Global Minimally-Invasive Cosmetic Procedures Market Research Report, By Procedures (Microdermabrasion), Products (Hair Removal Lasers, Botulinum Toxins), Application (Acne & Trauma Scars), And End-Users (Dermatology Clinics) – Global Forecast Till 2027
  • Asia-Pacific Aesthetic Services Market Size, Status and Forecast 2021-2027
  • Global Mobile Testing Market 2021 by Company, Regions, Type and Application, Forecast to 2026
  • Global Ground and Cargo Handling Services Market 2021 by Company, Regions, Type and Application, Forecast to 2026
  • Global Cemented Carbide Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

    • ◆H&Iグローバルリサーチのお客様（例）◆